BCRX vs IP · rev $374.7M vs P/E 43, rev $11.97B
BioCryst Pharmaceuticals Inc (BCRX) versus International Paper (IP) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
International Paper (IP) is a packaging & containers company listed on US.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
Latest reported IP revenue for 2026-06-30 was $11.97B. Net income was $48.0M. IP currently screens at market cap $26.62B and trailing P/E 43.1.
BCRX currently screens at market cap $1.83B. IP currently screens at market cap $26.62B and trailing P/E 43.1.
Not investment advice. Open the BCRX and IP stock pages for the full models.
Not investment advice.